ERBB2 and breast carcinoma: Looking at Ki67 values in different molecular subtypes, it seemed that patients with triple-negative or hormone receptor-positive, HER2-negative breast cancer had a more favorable prognosis when a pCR was achieved, although these patient groups had a higher Ki67 proliferation rate.